{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McCarthy EM"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","NIH","Wellcome Trust"],"pagination":["470-479"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5850287"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(3)"],"pubmed_abstract":["<h4>Objectives</h4>To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use.<h4>Methods</h4>Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to ⩽ 1 B score with no new A/B scores in other organ systems at 6 months.<h4>Results</h4>Two hundred and seventy SLE patients commenced biologic therapy from September 2010 to September 2015, most commonly RTX (n = 261). Two hundred and fifty (93%) patients were taking glucocorticoids at baseline "],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register."],"pmcid":["PMC5850287"],"funding_grant_id":["NF-SI-0515-10015","NF-SI-0512-10105","NF-SI-0617-10075","MR/M01665X/1"],"pubmed_authors":["Nesbit S","Rahman A","Edwards CJ","Bruce IN","Sutton E","Teh LS","British Isles Lupus Assessment Group Biologics Register","White J","Lanyon P","Zoma A","Yee CS","Parker B","Griffiths B","Jayne D","Vital EM","McCarthy EM","McHugh NJ","Isenberg DA","Gordon C","D'Cruz DP","Rhodes B","Akil M"],"additional_accession":[]},"is_claimable":false,"name":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.","description":"<h4>Objectives</h4>To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK and to explore short term efficacy and infection rates associated with rituximab (RTX) use.<h4>Methods</h4>Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to ⩽ 1 B score with no new A/B scores in other organ systems at 6 months.<h4>Results</h4>Two hundred and seventy SLE patients commenced biologic therapy from September 2010 to September 2015, most commonly RTX (n = 261). Two hundred and fifty (93%) patients were taking glucocorticoids at baseline ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Mar","modification":"2025-04-18T20:15:42.113Z","creation":"2019-03-26T23:22:56Z"},"accession":"S-EPMC5850287","cross_references":{"pubmed":["29216396"],"doi":["10.1093/rheumatology/kex395"]}}